GLP-1 and Surgical Anesthesia: The Fasting Debate

GLP-1 receptor agonists slow gastric emptying — that's part of how they reduce appetite. But it also means food may remain in the stomach longer than expected before surgery, increasing the risk of pulmonary aspiration during anesthesia. In 2023, the American Society of Anesthesiologists issued updated guidance. The debate continues about optimal management.

The concern is straightforward: anesthesia suppresses protective reflexes, including the ability to prevent stomach contents from entering the lungs (aspiration). Standard preoperative fasting guidelines (NPO after midnight, or 2 hours for clear liquids / 6–8 hours for solids) were developed based on normal gastric emptying rates. GLP-1 drugs extend gastric emptying time by 30–50%, which means patients who followed standard fasting protocols may still have residual gastric contents at the time of induction.

What the ASA Recommends

In June 2023, the American Society of Anesthesiologists issued guidance on managing patients taking GLP-1 drugs preoperatively. The key recommendations include considering holding GLP-1 medications before elective procedures — specifically, holding daily formulations (oral semaglutide) for the day of surgery and weekly injectables (Ozempic, Wegovy, Mounjaro, Zepbound) for at least one dosing interval (one week) before the procedure.

For patients who have not held their GLP-1 medication, or who report GI symptoms (nausea, bloating, vomiting, abdominal pain), the ASA recommends point-of-care gastric ultrasound to assess stomach contents before proceeding with anesthesia. If significant gastric volume is identified, options include delaying the procedure, proceeding with a rapid-sequence induction (which provides additional airway protection), or treating the residual contents with prokinetic agents.

The Clinical Tension

The ASA guidance creates a clinical tension. Holding a weekly GLP-1 injection for a week means missing a dose, which can precipitate nausea, appetite changes, and blood glucose fluctuations (in diabetic patients) when restarting. For patients on GLP-1 drugs for diabetes management, stopping the drug also removes its glycemic control benefits during the perioperative period — a time when blood glucose management is already challenging.

The evidence base for these recommendations is limited. The ASA guidance was developed by expert consensus, not from randomized trials. The actual incidence of clinically significant aspiration events attributable to GLP-1 use is unknown, and case reports are sparse. Some anesthesiologists argue that the theoretical risk has been overstated and that point-of-care gastric ultrasound is sufficient without requiring medication holds.

What Patients Should Do

If you're taking a GLP-1 medication and have an upcoming surgical procedure requiring general anesthesia or deep sedation, inform your surgeon and anesthesiologist. Don't stop your medication without consulting your prescribing physician — the decision to hold the drug should be made collaboratively, weighing aspiration risk against metabolic management.

For emergency procedures, the GLP-1 status doesn't change urgent surgical decisions — rapid-sequence induction and aspiration precautions are standard for any patient with an uncertain fasting status.